Abiopharma

🔍 Yates Daniel S. (Executive)

Company: Dynatrace, Inc. (DT)

Report Date: 2026-06-05

Detailed Transactions and Holdings:

• Acquired 2,409 shares of Common Stock (Direct)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 31,991.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 1,069 shares of Common Stock at $42.19 per share (Direct)
  Date: 2026-06-05 | Code: F | equity_swap_involved: 0 | shares_owned_after: 30,922.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 560 shares of Common Stock (Direct)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 31,482.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 249 shares of Common Stock at $42.19 per share (Direct)
  Date: 2026-06-05 | Code: F | equity_swap_involved: 0 | shares_owned_after: 31,233.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 718 shares of Common Stock (Direct)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 31,951.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 319 shares of Common Stock at $42.19 per share (Direct)
  Date: 2026-06-05 | Code: F | equity_swap_involved: 0 | shares_owned_after: 31,632.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 703 shares of Common Stock (Direct)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 32,335.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 312 shares of Common Stock at $42.19 per share (Direct)
  Date: 2026-06-05 | Code: F | equity_swap_involved: 0 | shares_owned_after: 32,023.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 2,670 shares of Common Stock (Direct)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 34,693.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 1,185 shares of Common Stock at $42.19 per share (Direct)
  Date: 2026-06-05 | Code: F | equity_swap_involved: 0 | shares_owned_after: 33,508.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 1,825 shares of Common Stock (Direct)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 35,333.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 810 shares of Common Stock at $42.19 per share (Direct)
  Date: 2026-06-05 | Code: F | equity_swap_involved: 0 | shares_owned_after: 34,523.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 2,409 shares of Performance Restricted Stock Units (Financial) (Derivative)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F3, F1
• Sold 560 shares of Performance Restricted Stock Units (Financial) (Derivative)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 2,238.00 | transaction_form_type: 4 | Footnotes: F1, F4, F1
• Sold 718 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 2,873.00 | transaction_form_type: 4 | Footnotes: F1, F5, F1
• Sold 703 shares of Performance Restricted Stock Units (rTSR) (Derivative)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F6, F1
• Sold 2,670 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 5,419.00 | transaction_form_type: 4 | Footnotes: F1, F7, F1
• Sold 1,825 shares of Performance Restricted Stock Units (Financial) (Derivative)
  Date: 2026-06-05 | Code: M | equity_swap_involved: 0 | shares_owned_after: 3,700.00 | transaction_form_type: 4 | Footnotes: F1, F8, F1
• Acquired 8,889 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-05 | Code: A | equity_swap_involved: 0 | shares_owned_after: 8,889.00 | transaction_form_type: 4 | Footnotes: F1, F9, F1

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units do not expire. They either vest or are cancelled prior to the vesting date.
• F2: Shares withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations upon the vesting of restricted stock units.
• F3: Represents the vesting of restricted stock units based on financial performance ("Financial PSUs") granted on October 15, 2023 under the Issuer's 2019 Equity Incentive Plan, as amended (the "Plan"). 33% of the Financial PSUs granted vested on June 5, 2024 and the balance of the Financial PSUs vested in equal quarterly installments thereafter until fully vested on June 5, 2026.
• F4: Represents the vesting of Financial PSUs granted on June 5, 2024 under the Plan. 33% of the Financial PSUs granted vested on June 5, 2025 and the balance of the Financial PSUs vest in equal quarterly installments thereafter until fully vested on June 5, 2027, subject to the Reporting Person's continued employment on the applicable vesting dates.
• F5: Represents the vesting of time-based restricted stock units ("RSUs") granted on June 5, 2024 under the Plan. 33% of the RSUs granted vested on June 5, 2025 and the balance of the RSUs vest in equal quarterly installments thereafter until fully vested on June 5, 2027, subject to the Reporting Person's continued employment on the applicable vesting dates.
• F6: Represents the vesting of restricted stock units based on relative total stockholder return ("rTSR PSUs") granted on June 5, 2024 under the Plan. These rTSR PSUs were earned following certification by the Compensation Committee of the Board of Directors of the Issuer (the "Compensation Committee") of certain performance conditions related to relative total stockholder return for the two year performance period that started on April 1, 2024 and ended on March 31, 2026. All of these rTSR PSUs vested on June 5, 2026.
• F7: Represents the vesting of RSUs granted on June 5, 2025 under the Plan. 33% of the RSUs vested on June 5, 2026 and the balance of the RSUs vest in equal quarterly installments thereafter until fully vested on June 5, 2028, subject to the Reporting Person's continued employment on the applicable vesting dates.
• F8: Represents the vesting of Financial PSUs granted on June 5, 2025 under the Plan and earned following certification by the Compensation Committee of certain financial performance results for the Issuer's fiscal year 2026 that started on April 1, 2025 and ended on March 31, 2026. 33% of the Financial PSUs vested on June 5, 2026, and the balance of the Financial PSUs vest in equal quarterly installments thereafter until fully vested on June 5, 2028, subject to the Reporting Person's continued employment on the applicable vesting dates.
• F9: Represents the grant of RSUs under the Plan. 33% of these RSUs will vest on June 5, 2027 and the balance of the RSUs will vest in equal quarterly installments thereafter until fully vested on June 5, 2029, subject to the Reporting Person's continued employment on the applicable vesting dates.